Cinacalcet hydrochloride (Sensipar - Amgen) has been approved by the FDA for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and treatment of hypercalcemia in patients with parathyroid carcinoma.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
Print version published and mailed biweekly (26 issues/year)
Immediate Online access to current issue and archives from 1988 to the present
Mobile access to our mobile site and free apps for iOS, Android and Kindle